Sign up to save your podcasts
Or
Share Dr. Louis Chicoine Discusses the Effect of Plasmapheresis in Removal of AAV Antibodies for Gene Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dr. Louis Chicoine Discusses the Effect of Plasmapheresis in Removal of AAV Antibodies for Gene Therapy
Dr. Louis Chicoine Discusses the Effect of Plasmapheresis in Removal of AAV Antibodies for Gene Therapy :: November 2013
Guest: Louis Chicoine, MD, principal investigator in the Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital; assistant professor of Pediatrics at The Ohio State University College of Medicine.
Access an abstract of this month’s featured research article:
Plasmapheresis eliminates the negative impact of AAV antibodies on micro-dystrophin gene expression following vascular delivery. Molecular Therapy. 2013 Oct 23. [Epub ahead of print]
Major contributors to the work described include the Jesse’s Journey Foundation, the Nationwide Children’s Hospital Foundation, the Muscular Dystrophy Association, a National Institutes of Health grant (U54 NS055958), and a Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center grant (U54 HD066409).
View all episodes
By Kevin Flanigan, MDDr. Louis Chicoine Discusses the Effect of Plasmapheresis in Removal of AAV Antibodies for Gene Therapy :: November 2013
Guest: Louis Chicoine, MD, principal investigator in the Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital; assistant professor of Pediatrics at The Ohio State University College of Medicine.
Access an abstract of this month’s featured research article:
Plasmapheresis eliminates the negative impact of AAV antibodies on micro-dystrophin gene expression following vascular delivery. Molecular Therapy. 2013 Oct 23. [Epub ahead of print]
Major contributors to the work described include the Jesse’s Journey Foundation, the Nationwide Children’s Hospital Foundation, the Muscular Dystrophy Association, a National Institutes of Health grant (U54 NS055958), and a Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center grant (U54 HD066409).